抗糖尿病药物类别对2型糖尿病合并代谢功能障碍相关脂肪性肝病患者肝脏相关事件风险的影响
这项回顾性队列研究纳入16家三级转诊中心2004年2月至2023年1月间7867例2型糖尿病合并代谢功能障碍相关脂肪性肝病患者,记录吡格列酮、GLP-1受体激动剂和SGLT-2抑制剂的使用,中位随访5.1年,分析这些药物对肝脏相关事件发生风险和肝硬度进展的影响。
要点
- SGLT-2抑制剂使用与肝脏相关事件风险降低相关(亚分布风险比0.23,95%CI 0.08-0.69,P=.009)。
- SGLT-2抑制剂使用与肝硬度进展风险降低相关(风险比0.54,95%CI 0.35-0.86,P=.008)。
- SGLT-2抑制剂在亚洲国家比西方国家处方更频繁(34.4% vs 7.3%,P<.001)。
核心结论
- SGLT-2抑制剂在亚洲个体中比西方个体更普遍使用。
- SGLT-2抑制剂与2型糖尿病合并MASLD个体肝脏相关事件风险降低相关。
研究设计与样本
- 回顾性队列研究,纳入16家三级转诊中心2004年2月至2023年1月间7867例2型糖尿病合并MASLD个体。
- 记录吡格列酮、GLP-1受体激动剂和SGLT-2抑制剂的使用,中位随访5.1年。
主要发现
- 吡格列酮、GLP-1受体激动剂和SGLT-2抑制剂分别处方于1238例(15.7%)、863例(11.0%)和2386例(30.3%)个体。
- 从2010-2017年到2017-2023年,GLP-1受体激动剂和SGLT-2抑制剂的使用显著增加。
- 吡格列酮和SGLT-2抑制剂在亚洲国家比西方国家处方更频繁(吡格列酮:17.9% vs 3.8%;SGLT-2抑制剂:34.4% vs 7.3%;P<.001)。
- 倾向评分匹配后,在竞争风险模型中,调整潜在混杂因素后,SGLT-2抑制剂使用与肝脏相关事件风险降低显著相关(亚分布风险比0.23;95%CI 0.08-0.69,P=.009)。
- SGLT-2抑制剂使用与肝硬度进展风险降低显著相关(风险比0.54;95%CI 0.35-0.86,P=.008)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We investigated the use of type 2 diabetes (T2D) medications, including pioglitazone, glucagon-like peptide-1 receptor agonists (GLP-1RAs), and sodium-glucose cotransporter-2 (SGLT-2) inhibitors, in individuals with T2D and metabolic dysfunction-associated steatotic liver disease (MASLD), and explored the effect of these medications on long-term risk of liver-related events (LREs) and progression of liver stiffness in a retrospective cohort study. METHODS: We enrolled 7867 individuals with T2D and MASLD from 16 tertiary referral centers between February 2004 and January 2023. We recorded the use of pioglitazone, GLP-1RAs, and SGLT-2 inhibitors and analyzed the effects of these antihyperglycemic medications on the risk of developing incident LREs and the progression of liver stiffness over a median of 5.1 years of follow-up. RESULTS: Pioglitazone, GLP-1RAs and SGLT-2 inhibitors were prescribed to 1238 (15.7%), 863 (11.0%), and 2386 (30.3%) individuals with T2D and MASLD, respectively. A significant increase in the utilization of GLP-1RAs and SGLT-2 inhibitors was observed from 2010-2017 to 2017-2023, with pioglitazone and SGLT-2 inhibitors being prescribed more frequently in Asian countries than in Western countries (pioglitazone: 17.9% vs 3.8%; SGLT-2 inhibitors: 34.4% vs 7.3%; P < .001). After propensity score matching, in competing risk models, SGLT-2 inhibitor use was significantly associated with a lower risk of developing both LREs (subdistribution hazard ratio, 0.23; 95% confidence interval, 0.08-0.69, P = .009) and liver stiffness progression (hazard ratio, 0.54; 95% confidence interval, 0.35-0.86, P = .008) after adjusting for potential confounders. CONCLUSIONS: SGLT-2 inhibitor use is more prevalent among Asian than Western individuals. SGLT-2 inhibitors are associated with a lower risk of LREs in individuals with T2D and MASLD.
引用
- Shi Y, Kim SU, Yip TC, et al. Effect of Antidiabetic Drug Classes on the Risk of Liver-Related Events in Individuals With T2D and MASLD. Clin Gastroenterol Hepatol. 2025. PMID: 40490148. doi:10.1016/j.cgh.2025.06.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。